XOMA Royalty - 8.375% PRF PERPETUAL USD 25 - Ser B 1/1000th EBIT

The latest EBIT for XOMAO is $5.1M as of March 2026. That compares with $-17M in the prior-year period — up 129.8% year over year. That is below the Healthcare sector average of $22B. Investors often review this figure alongside XOMA Royalty - 8.375% PRF PERPETUAL USD 25 - Ser B 1/1000th's historical trend and sector peers before judging valuation or financial health.

Over the past year, XOMAO's EBIT moved from $-17M to $5.1M — a 129.8% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in XOMA Royalty - 8.375% PRF PERPETUAL USD 25 - Ser B 1/1000th's operating scale or balance-sheet position.

Against Healthcare companies, XOMAO currently prints $5.1M for EBIT, while the sector average sits near $22B. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at XOMA Royalty - 8.375% PRF PERPETUAL USD 25 - Ser B 1/1000th's growth, margins, and balance sheet.

A EBIT figure of $5.1M for XOMAO is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $22B. Explore the charts below for those layers of context.

After noting XOMAO's EBIT ($5.1M), review year-over-year change from $-17M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.